Alpha DNA Investment Management LLC Acquires New Shares in Exelixis, Inc. (NASDAQ:EXEL)

Alpha DNA Investment Management LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 14,397 shares of the biotechnology company’s stock, valued at approximately $479,000.

Other institutional investors also recently bought and sold shares of the company. MML Investors Services LLC grew its position in shares of Exelixis by 9.9% in the third quarter. MML Investors Services LLC now owns 22,958 shares of the biotechnology company’s stock valued at $596,000 after purchasing an additional 2,077 shares during the last quarter. Sanctuary Advisors LLC grew its holdings in Exelixis by 42.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 39,261 shares of the biotechnology company’s stock valued at $1,019,000 after buying an additional 11,757 shares during the last quarter. Tidal Investments LLC increased its position in Exelixis by 2.3% during the third quarter. Tidal Investments LLC now owns 36,366 shares of the biotechnology company’s stock worth $944,000 after buying an additional 823 shares in the last quarter. Tri Ri Asset Management Corp acquired a new position in shares of Exelixis in the third quarter worth $4,396,000. Finally, Retirement Systems of Alabama raised its holdings in shares of Exelixis by 24.6% in the third quarter. Retirement Systems of Alabama now owns 911,497 shares of the biotechnology company’s stock worth $23,653,000 after acquiring an additional 180,021 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the sale, the executive vice president now owns 303,310 shares of the company’s stock, valued at $11,216,403.80. The trade was a 14.79 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares in the company, valued at $1,060,561.28. This represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on EXEL. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Exelixis in a research report on Thursday, March 27th. StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 19th. BMO Capital Markets lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and boosted their price objective for the company from $36.00 to $40.00 in a research report on Friday, December 20th. UBS Group restated an “underperform” rating on shares of Exelixis in a research report on Thursday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a report on Thursday. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Trading Up 0.1 %

Shares of EXEL stock opened at $36.19 on Friday. The company has a market cap of $10.13 billion, a PE ratio of 20.45, a P/E/G ratio of 1.13 and a beta of 0.57. The company’s fifty day simple moving average is $36.44 and its 200-day simple moving average is $34.25. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Equities research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.